IP Library Granted Patent US 8,273,580
Granted Patent B2
US 8,273,580 · App. 13/176,655 · Granted Sep 25, 2012

Method of measuring the concentration of a glycosaminoglycan anticoagulant

Assignee: Active BioMaterials, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,273,580
App. No.
13/176,655
Granted
Sep 25, 2012
Kind
B2
Abstract

The invention provides an accurate, economical, automatable, high throughput method for the determination of the concentration of glycosaminoglycan anticoagulants, including low molecular weight heparin (LMWH) anticoagulants, in aqueous solutions. A method for cleaning a unit of manufacturing equipment used in the preparation of a LMWH to obtain an acceptable residual concentration of LMWH is further provided.

Claims (21)

1. A method of cleaning a unit of manufacturing equipment used in the preparation of heparin to obtain an acceptable residual concentration of heparin comprising:

(a) subjecting the unit of manufacturing equipment to a cleaning protocol;

(b) obtaining the absorbance of a sample obtained from the manufacturing equipment comprising:

(i) collecting a sample from the manufacturing equipment;

(ii) reacting the sample with 1,9-dimethyl-methylene blue; and

(iii) determining the absorbance of the sample reacted with 1,9 dimethyl methylene blue;

(c) determining the concentration of heparin in the sample obtained from the manufacturing equipment by comparing its absorbance with the absorbances of a plurality of samples of control heparin in aqueous solutions of known concentrations; and

(d) optionally repeating steps (a)-(c) until the concentration of heparin in the sample obtained from the manufacturing equipment is less than an acceptable residual concentration of heparin.

2. The method of claim 1 , wherein in step (c) the absorbance of the heparin sample is compared to a standard curve of absorbances obtained from a plurality of samples having known concentrations of the heparin.

3. The method of claim 2 , wherein the standard curve of absorbances of samples having known concentrations of the heparin is obtained by a process comprising:

(a) preparing a plurality of samples of known heparin concentration;

(b) reacting the samples of known heparin concentration with 1,9-dimethyl-methylene blue;

(c) determining the absorbance of the samples of known heparin concentration reacted with 1,9 dimethyl-methylene blue; and

(d) graphing the absorbances obtained in step (c) versus the known heparin concentrations of the corresponding samples.

4. The method of claim 1 , wherein a plurality of samples are obtained from the manufacturing equipment.

5. The method of claim 4 , wherein the plurality of samples obtained from the unit of manufacturing equipment are obtained from the surface of one or more of a holding container, a mixing container, a reaction container, a low flow conduit, a high flow conduit, and a dispensing device.

6. The method of claim 1 , wherein the absorbances of the sample and the samples of known concentration are determined in a microtiter plate or a cuvette.

7. The method of claim 1 , wherein the sample from the manufacturing equipment is obtained by swabbing, scrubbing, rinsing, scraping or wiping a surface of the unit of manufacturing equipment.

8. The method of claim 1 , wherein the acceptable residual concentration of heparin is less than about 7.8 micrograms per square inch of surface area.

9. The method of claim 1 , wherein the acceptable residual concentration of heparin is less than about 1.0 micrograms per milliliter of sample.

10. The method of claim 1 , wherein the acceptable residual concentration of heparin is less than about 1.8 micrograms per milliliter of sample.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2020
From: YAMAMOTO, RALPH
To: ABRAXIS BIOSCIENCE, INC.
Reel/Frame 052578/0277 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2020
From: CALIFORNIA CAPITAL EQUITY, LLC
To: ACTIVE BIOMATERIALS, LLC
Reel/Frame 052578/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2020
From: ABRAXIS BIOSCIENCE, INC.; ABRAXIS BIOSCIENCE, LLC
To: CALIFORNIA CAPITAL EQUITY, LLC
Reel/Frame 052578/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2020
From: KIM, YUMI
To: ACTIVE BIOMATERIALS, LLC
Reel/Frame 052578/0292 →
MERGER Recorded May 5, 2020
From: ABRAXIS BIOSCIENCE, INC.
To: ABRAXIS BIOSCIENCE, LLC
Reel/Frame 052581/0135 →
Continuity (3)
Continuation 12179434 · Jul 24, 2008
Provisional Application 60951504 · Jul 24, 2007
Related Publication 20120009686A1 · Jan 12, 2012